Strekin AG (www.strekin.com), a clinical stage biopharmaceutical company, announced that it has successfully closed a Series A financing round totaling CHF 2.82 Million (USD $2.86 million) from private investors. These funds will enable Strekin to conclude its ongoing Phase 3 clinical trial of STR001 in Sudden Sensorineural Hearing Loss, the RESTORE trial, and to prepare for a European filing.
STR001 is Strekin’s lead drug candidate. Preclinical data published by Strekin and its collaborators demonstrated that STR001 effectively protects hearing in animal models by blocking oxidative stress and reducing activation of inflammatory signaling in the cochlea. The RESTORE trial is an international, randomized, placebo-controlled Phase 3 clinical trial of STR001 in patients suffering from a sudden sensorineural hearing loss event. STR001 is said to have been “very well-tolerated” and topline results from RESTORE are anticipated to be released in early 2020.
“With the funding from Series A we have now the financial flexibility to finish the ongoing clinical study, to prepare an NDA filing in Europe, and to drive a corporate exit either via IPO or trade sale,” said Alexander Bausch, Strekin’s Chief Executive Office and founder. “The RESTORE trial tests the ability of STR001 to address a clear unmet medical need in patients who have suffered an event that may lead to severe, lifelong hearing loss. If successful, the data provided by RESTORE, along with the orphan drug status of STR001 for SSNHL, may allow Strekin to quickly launch STR001 in Europe.”
Source: Strekin AG
